Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency
NCT01230021
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
6
Enrollment
INDUSTRY
Sponsor class
Conditions
Congenital Bleeding Disorder
Congenital FXIII Deficiency
Interventions
DRUG:
catridecacog
Sponsor
Novo Nordisk A/S